New crowdsourcing project to examine the ‘Advanced Biomarker Detection for Pharmacological Monitoring in the Brain’
Talented young scientists from the world’s top universities and research institutions are invited to submit innovative project proposals and apply for a research fellowship at the BioMed X Institute in Heidelberg.
BioMed X and Boehringer Ingelheim started their partnership in 2014 and since then have initiated four preclinical research projects in the fields of respiratory diseases, neuroscience, and immunology.
HEIDELBERG, Germany, March 29, 2021 / B3C newswire / -- German independent research institute BioMed X announces its new global call with Boehringer Ingelheim, which will strive to identify creative ideas for improved in vivo PK/PD sensor platforms supporting the continuous, real-time measurement of specific small molecules directly in brain tissue of rodent models (i.e. pharmacological substances, their metabolites, or pharmacologically triggered effector molecules).
Christian Tidona, Founder and Managing Director of the BioMed X Institute: “The process of developing active drugs for the treatment of neuropsychiatric diseases involves establishing a robust relationship between the pharmacodynamic (PD) effect and the pharmacokinetic (PK) parameters of the new drug candidate for taking PK/PD-based decisions. We are very pleased to see that Boehringer Ingelheim has decided to further strengthen our existing partnership in the field of neurosciences with this new research topic.”
As part of the online application procedure, interested candidates are requested to submit a competitive project proposal. After a first selection round, candidates will be invited to a five-day innovation boot camp in Heidelberg. If pandemic regulations do not allow onsite meetings, the boot camp will take place online.
The BioMed X Institute has been working closely with Boehringer Ingelheim since 2014. Two projects in lung research and neuroscience have already been successfully completed. This new call for application is now being added to two ongoing programs in the fields of immunology (Pathogen-Mediated Modulation of Innate Immunity) and neuroscience (Early Intervention in Psychiatric Diseases).
Further details about this call for application can be found on the website of the BioMed X Institute at www.bio.mx. Interested candidates are invited to apply via the BioMed X crowdsourcing platform at www.bio.mx/apply before May 23, 2021.